
CLAIMS

1. A pharmaceutical composition in oral solution dosage form comprising:

(a) a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof;

(b) one or more of a sweetener, an anti-oxidant, and a flavor; and

(c) medium-chain triglycerides.

2. The pharmaceutical composition of claim 1, comprising about 1 w/v% to about 50 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

3. The pharmaceutical composition of claim 1, comprising about 1 w/v% to about 10 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

4. The pharmaceutical composition of claim 1, comprising about 5 w/v% of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

5. The pharmaceutical composition of any one of claims 1 to 4, comprising a sweetener.

6. The pharmaceutical composition of any one of claims 1 to 5, comprising about 0.01 w/v% to about 1.5 w/v% of the sweetener.

7. The pharmaceutical composition of any one of claims 1 to 5, comprising about 0.1 w/v% to about 0.5 w/v% of the sweetener.

8. The pharmaceutical composition of any one of claims 1 to 5, comprising about 0.15 w/v% of the sweetener.

9. The pharmaceutical composition of any one of claims 1 to 8, wherein the sweetener is selected from saccharin, sucrose, sucralose, aspartame, dextrose, fructose, maltitol, mannitol, sorbitol, and avantame.

10. The pharmaceutical composition of any one of claims 1 to 9, wherein the sweetener is saccharin.

11. The pharmaceutical composition of any one of claims 1 to 10, comprising an anti-oxidant.

12. The pharmaceutical composition of any one of claims 1 to 11, comprising about 0.01 w/v% to about 1.5 w/v% of the anti-oxidant.

13. The pharmaceutical composition of any one of claims 1 to 11, comprising about 0.1 w/v% to about 0.5 w/v% of the anti-oxidant.

14. The pharmaceutical composition of any one of claims 1 to 11, comprising about 0.17 w/v% of the anti-oxidant.

15. The pharmaceutical composition of any one of claims 1 to 14, wherein the anti-oxidant is selected from butylated hydroxytoluene, vitamin E TPGS, butylated hydroxyanisole, ascorbic acid, lecithin, tert-butylhydroquinone, and citric acid.

16. The pharmaceutical composition of any one of claims 1 to 15, wherein the anti-oxidant is butylated hydroxytoluene.

17. The pharmaceutical composition of any one of claims 1 to 16, comprising a flavor.

18. The pharmaceutical composition of any one of claims 1 to 17, comprising about 0.01 w/v% to about 0.5 w/v% of the flavor.

19. The pharmaceutical composition of any one of claims 1 to 17, comprising about 0.05 w/v% to about 0.2 w/v% of the flavor.

20. The pharmaceutical composition of any one of claims 1 to 17, comprising about 0.10 w/v% of the flavor.

21. The pharmaceutical composition of any one of claims 1 to 20, wherein the flavor is selected from FONA orange flavor, FONA Juicy Flavor, FONA Grape Flavor, Firmenich SA Lemon Flavor, Firmenich Tetrarome Orange Flavor, IFF Cherry Flavor, and IFF Grape Flavor.

22. The pharmaceutical composition of any one of claims 1 to 21, wherein the flavor is FONA orange flavor.

23. The pharmaceutical composition of any one of claims 1 to 22, comprising about 50 w/v% to about 99.9 w/v% of the medium-chain triglycerides.

24. The pharmaceutical composition of any one of claims 1 to 22, comprising about 90 w/v% to about 99 w/v% of the medium-chain triglycerides.

25. The pharmaceutical composition of any one of claims 1 to 22, comprising about 92 w/v% to about 97 w/v% of the medium-chain triglycerides.

26. The pharmaceutical composition of any one of claims 1 to 22, comprising about 94.6 w/v% of the medium-chain triglycerides.

27. The pharmaceutical composition of any one of claims 1 to 22, comprising about 70 w/v% to about 80 w/v% of the medium-chain triglycerides.

28. The pharmaceutical composition of any one of claims 1 to 22, comprising about 75 w/v% of the medium-chain triglycerides.

29. The pharmaceutical composition of any one of claims 1 to 28, wherein the medium-chain triglycerides are Labrafac Lipophile WL1349.

30. The pharmaceutical composition of any one of claims 1 to 29, further comprising a surfactant.

31. The pharmaceutical composition of claim 30, comprising about 1 w/v% to about 50 w/v% of the surfactant.

32. The pharmaceutical composition of claim 30, comprising about 10 w/v% to about 30 w/v% of the surfactant.

33. The pharmaceutical composition of claim 30, comprising about 20 w/v% of the surfactant.

34. The pharmaceutical composition of any one of claims 30 to 33, wherein the surfactant is selected from oleoyl polyoxyl-6 glycerides, linoleoyl polyoxyl-6 glycerides, Polysorbate 80, Polysorbate 20, vitamin E polyethylene glycol succinate, Gelucire, lauroyl polyoxyl-32 glycerides, sodium lauryl sulfate, Poloxamer, corn oil PEG-6 esters, and hydrogenated palm/palm kernel oil PEG-6 esters.

35. The pharmaceutical composition of any one of claims 30 to 34, wherein the surfactant is oleoyl polyoxyl-6 glycerides.

36. The pharmaceutical composition of any one of claims 34 to 35, wherein the oleoyl polyoxyl-6 glycerides are LABRAFIL M 1944 CS.

37. The pharmaceutical composition of any one of claims 1 to 36, wherein the medium-chain triglycerides are Labrafac Lipophile WL1349.

38. The pharmaceutical composition of claim 1, comprising:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;

(b) a sweetener;

(c) an anti-oxidant;

(d) a flavor; and

(e) medium-chain triglycerides.

39. The pharmaceutical composition of claim 38, further comprising a surfactant.

40. The pharmaceutical composition of claim 1, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on free base weight;

(b) about 0.1 w/v% to about 0.2 w/v% of a sweetener;

(c) about 0.1 w/v% to about 0.2 w/v% of an anti-oxidant;

(d) about 0.05 w/v% to about 0.2 w/v% of a flavor; and

(e) about 92 w/v% to about 97 w/v% of medium-chain triglycerides.

41. The pharmaceutical composition of claim 1, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on free base weight;

(b) about 0.15 w/v% of a sweetener;

(c) about 0.17 w/v% of an anti-oxidant;

(d) about 0.1 w/v% of a flavor; and

(e) about 94.6 w/v% of medium-chain triglycerides.

42. The pharmaceutical composition of claim 1, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on free base weight;

(b) about 0.1 w/v% to about 0.2 w/v% of a sweetener;

(c) about 0.1 w/v% to about 0.2 w/v% of an anti-oxidant;

(d) about 0.05 w/v% to about 0.2 w/v% of a flavor;

(e) about 15 w/v% to about 25 w/v% of a surfactant; and

(f) about 70 w/v% to about 80 w/v% of medium-chain triglycerides.

43. The pharmaceutical composition of claim 1, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on free base weight;

(b) about 0.15 w/v% of a sweetener;

(c) about 0.17 w/v% of an anti-oxidant;

(d) about 0.1 w/v% of a flavor;

(e) about 20 w/v% of a surfactant; and

(f) about 75 w/v% of medium-chain triglycerides.

44. The pharmaceutical composition of claim 1, comprising:

(a) 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof;

(b) saccharin;

(c) butylated hydroxytoluene;

(d) FONA orange flavor; and

(e) medium-chain triglycerides.

45. The pharmaceutical composition of claim 44, further comprising oleoyl polyoxyl-6 glycerides.

46. The pharmaceutical composition of claim 45, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on free base weight;

(b) about 0.1 w/v% to about 0.2 w/v% of saccharin;

(c) about 0.1 w/v% to about 0.2 w/v% of butylated hydroxytoluene;

(d) about 0.05 w/v% to about 0.2 w/v% of FONA orange flavor; and

(e) about 92 w/v% to about 97 w/v% of medium-chain triglycerides.

47. The pharmaceutical composition of claim 1, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on free base weight;

(b) about 0.15 w/v% of saccharin;

(c) about 0.17 w/v% of butylated hydroxytoluene;

(d) about 0.1 w/v% of FONA orange flavor; and

(e) about 94.6 w/v% of medium-chain triglycerides.

48. The pharmaceutical composition of claim 1, comprising:

(a) about 4 w/v% to about 6 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on free base weight;

(b) about 0.1 w/v% to about 0.2 w/v% of saccharin;

(c) about 0.1 w/v% to about 0.2 w/v% of butylated hydroxytoluene;

(d) about 0.05 w/v% to about 0.2 w/v% of FONA orange flavor;

(e) about 15 w/v% to about 25 w/v% of oleoyl polyoxyl-6 glycerides; and

(f) about 70 w/v% to about 80 w/v% of medium-chain triglycerides.

49. The pharmaceutical composition of claim 1, comprising:

(a) about 5 w/v% of 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, or a pharmaceutically acceptable salt thereof, based on free base weight;

(b) about 0.15 w/v% of saccharin;

(c) about 0.17 w/v% of butylated hydroxytoluene;

(d) about 0.1 w/v% of FONA orange flavor;

(e) about 20 w/v% of oleoyl polyoxyl-6 glycerides; and

(f) about 75 w/v% of medium-chain triglycerides.

50. The pharmaceutical composition of claim 48 or 49, wherein:

the oleoyl polyoxyl-6 glycerides are LABRAFIL M 1944 CS; and

the medium-chain triglycerides are Labrafac TM Lipophile WL1349.

51. The pharmaceutical composition of any one of claims 1 to 50, comprising the compound of Formula (I) as a free base.

52. The pharmaceutical composition of any one of claims 1 to 51, formulated in unit dosage form, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 5 mg/mL to about 200 mg/mL, based on free base weight.

53. The pharmaceutical composition of claim 52, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 75 mg/mL to about 150 mg/mL, based on free base weight.

54. The pharmaceutical composition of claim 52, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 50 mg/mL, based on free base weight.

55. The pharmaceutical composition of claim 52, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is present in an amount of about 100 mg/mL, based on free base weight.

56. The pharmaceutical composition of any one of claims 1 to 55, having a viscosity between about 1 to about 50 centipoise at about 25 ^{o}C.

57. A method for preparing the pharmaceutical composition of any one of claims 1 to 56, comprising:

(a) mixing medium-chain triglycerides with a sweetener;

(b) mixing the mixture of step (a) with an anti-oxidant and a flavor;

(c) mixing the compound of Formula (I), or a pharmaceutically acceptable salt thereof, with the mixture of step (b); and

(d) mixing the mixture of step (c) with an additional portion of medium-chain triglycerides.

58. The method of claim 57, wherein step (a) comprises mixing medium-chain triglycerides with a sweetener and a surfactant.

59. Use of the pharmaceutical composition of any one of claims 1 to 56 in the manufacture of a medicament for treating congenital adrenal hyperplasia (CAH) in a subject.

60. The use according to claim 59, wherein the subject is in a fed state.

61. The use according to claim 59 or 60, wherein the subject is to be administered the pharmaceutical composition together with a nutritional composition.

62. The use according to claim 61, wherein the nutritional composition is a liquid dietary supplement comprising about 1000 to about 2000 calories per liter, having a fat content greater than about 30%.

63. The use according to claim 61, wherein the nutritional composition is a liquid dietary supplement comprising 1500 calories per liter, having a caloric distribution of 14.7% protein, 32% fat, and 53.3% carbohydrate.

64. The use according to any one of claims 61 to 63, wherein the nutritional composition is to be administered in an amount of about 6 to about 12 fluid ounces.

65. The use according to any one of claims 61 to 63, wherein the nutritional composition is to be administered in an amount of about 8 fluid ounces.

66. The use according to any one of claims 61 to 65, wherein the nutritional composition is to be administered within 30 minutes of administration of the pharmaceutical composition.

67. The use according to any one of claims 60 to 66, wherein administering the pharmaceutical composition exhibits a positive food effect.

68. The use according to claim 67, wherein the positive food effect is measured in terms of C_{max}, AUC, or a combination thereof of a compound of Formula (I) when comparing oral administration of the pharmaceutical composition in the fed state and a fasted state.

69. The use according to any one of claims 60 to 68, wherein a ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

70. The use according to any one of claims 60 to 68, wherein a ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

71. The use according to any one of claims 60 to 68, wherein a ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

72. The use according to any one of claims 60 to 68, wherein a ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

73. The use according to any one of claims 59 to 72, wherein the subject is a human subject.

74. The use according to any one of claims 60 to 66, wherein the pharmaceutical composition exhibits a positive food effect when administered orally.

75. The use according to claim 74, wherein the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 1 to about 4 or about 5 to about 10.

76. The use according to claim 74, wherein the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 1 to about 4 or about 5 to about 10.

77. The use according to claim 74, wherein the compound of Formula (I) has a ratio of the AUC in the fed state to the AUC in the fasted state of about 1.5 to about 3.

78. The use according to claim 74, wherein the compound of Formula (I) has a ratio of the C_{max} in the fed state to the C_{max} in the fasted state of about 1.5 to about 3.

79. The use according to any one of claims 59 to 78, wherein the pharmaceutical composition is to be administered to the subject together with a meal.

80 The use according to claim 79, wherein the meal is a high-fat meal.

81. The use according to claim 79, wherein the meal is a low-fat meal.

82. The use according to any one of claims 79 to 81, wherein the pharmaceutical composition is to be administered within about 5 minutes after the start of the meal.

83. The use according to any one of claims 79 to 82, wherein the meal is an evening meal.

84. The use according to any one of claims 79 to 82, wherein the meal is a morning meal.

85. The use according to any one of claims 79 to 84, wherein administering the pharmaceutical composition exhibits a positive food effect.

86. The use according to claim 85, wherein the positive food effect is measured in terms of C_{max}, AUC, or combinations thereof of the compound of Formula (I) when comparing oral administration of the pharmaceutical composition in the fed state and a fasted state.

87. The use according to any one of claims 79 to 86, wherein a ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

88. The use according to any one of claims 79 to 87, wherein a ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1 to about 4 or about 5 to about 10.

89. The use according to any one of claims 79 to 86, wherein a ratio of the AUC of the compound of Formula (I) in the fed state to the AUC of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

90. The use according to any one of claims 79 to 86 and 89, wherein a ratio of the C_{max} of the compound of Formula (I) in the fed state to the C_{max} of the compound of Formula (I) in the fasted state is about 1.5 to about 3.

91. The use according to any one of claims 59 to 90, wherein the pharmaceutical composition comprises about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

92. The use according to any one of claims 59 to 90, wherein the pharmaceutical composition comprises about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

93. The use according to any one of claims 59 to 90, wherein the pharmaceutical composition comprises about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

94. The use according to any one of claims 59 to 90, wherein the pharmaceutical composition comprises about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

95. The use according to any one of claims 59 to 90, wherein a daily dose of the pharmaceutical composition comprising about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight is to be administered.

96. The use according to any one of claims 59 to 90, wherein a daily dose of the pharmaceutical composition comprising about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight is to be administered.

97. The use according to any one of claims 59 to 90, wherein a daily dose of the pharmaceutical composition comprising about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight is to be administered.

98. The use according to any one of claims 59 to 90, wherein a daily dose of the pharmaceutical composition comprising about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight is to be administered.

99. The use according to any one of claims 59 to 90, wherein a daily dose of the pharmaceutical composition comprising about 150 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight is to be administered.

100. The use according to any one of claims 59 to 90, wherein a daily dose of the pharmaceutical composition comprising about 200 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight is to be administered.

101. The use according to any one of claims 59 to 90, wherein the pharmaceutical composition is to be administered twice daily in a dose of about 25 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

102. The use according to any one of claims 59 to 90, wherein the pharmaceutical composition is to be administered twice daily in a dose of about 50 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

103. The use according to any one of claims 59 to 90, wherein the pharmaceutical composition is to be administered twice daily in a dose of about 75 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

104. The use according to any one of claims 59 to 90, wherein the pharmaceutical composition is to be administered twice daily in a dose of about 100 mg of the compound of Formula (I), or a pharmaceutically acceptable salt thereof, based on free base weight.

105. The use according to any one of claims 59 to 104, wherein the subject concurrently receives a dose of a glucocorticoid.

106. The use according to claim 105, wherein the glucocorticoid is selected from cortisol (hydrocortisone), cortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, fludrocortisone acetate, and deoxycorticosterone acetate.

107. The use according to claim 105 or 106, wherein the glucocorticoid is cortisol (hydrocortisone).

108. The use according to claim 105 or 106, wherein the glucocorticoid is cortisone.

109. The use according to claim 105 or 106, wherein the glucocorticoid is prednisone.

110. The use according to any one of claims 105 to 109, wherein the glucocorticoid dose is measured in hydrocortisone equivalents.

111. The use according to any one of claims 105 to 110, wherein the glucocorticoid dose is measured as a multiple of a normal upper limit of physiologic dosing in hydrocortisone equivalents.

112. The use according to any one of claims 105 to 111, wherein the glucocorticoid dose is a physiologic dose as measured after a period of administration of the pharmaceutical composition.

113. The use according to any one of claims 105 to 111, wherein the glucocorticoid dose is a physiologic dose of about 4 to about 12 mg/m^2/day as measured after a period of administration of the pharmaceutical composition.

114. The use according to any one of claims 105 to 111, wherein the glucocorticoid dose is a physiologic dose of about 4 to about 9 mg/m^2/day as measured after a period of administration of the pharmaceutical composition.

115. The use according to any one of claims 105 to 111, wherein the glucocorticoid dose is a physiologic dose that is less than about 8 mg/m^2/day as measured after a period of administration of the pharmaceutical composition.

116. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by about 10% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition

117. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by about 20% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

118. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by about 30% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

119. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by about 40% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

120. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by about 50% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

121. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by about 60% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

122. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by about 70% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

123. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by less than about 20% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

124. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by about 20% to about 50% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

125. The use according to any one of claims 105 to 115, wherein the glucocorticoid dose of the subject is reduced by greater than about 50% after a period of administration of the pharmaceutical composition, wherein the reduction of the glucocorticoid dose is relative to the glucocorticoid dose prior to administration of the pharmaceutical composition.

126. The use according to any one of claims 59 to 125, wherein the level of 17-hydroxyprogesterone is reduced by at least about 25% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the pharmaceutical composition.

127. The use according to any one of claims 59 to 125, wherein the level of 17-hydroxyprogesterone is reduced by at least about 50% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of 17-hydroxyprogesterone is relative to the level of 17-hydroxyprogesterone prior to administration of the pharmaceutical composition.

128. The use according to any one of claims 59 to 125, wherein the level of 17-hydroxyprogesterone is less than about 1.5 times a normal upper limit after a period of administration of the pharmaceutical composition.

129. The use according to any one of claims 59 to 125, wherein the level of 17-hydroxyprogesterone is within normal limits after a period of administration of the pharmaceutical composition.

130. The use according to any one of claims 59 to 129, wherein the level of adrenocorticotropic hormone is reduced by at least about 25% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition.

131. The use according to any one of claims 59 to 129, wherein the level of adrenocorticotropic hormone is reduced by at least about 40% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition.

132. The use according to any one of claims 59 to 129, wherein the level of adrenocorticotropic hormone is reduced by at least about 50% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of adrenocorticotropic hormone is relative to the level of adrenocorticotropic hormone prior to administration of the pharmaceutical composition.

133. The use according to any one of claims 59 to 129, wherein the level of adrenocorticotropic hormone is less than about 1.5 times a normal upper limit after a period of administration of the pharmaceutical composition.

134. The use according to any one of claims 59 to 125, wherein the level of adrenocorticotropic hormone is within normal limits after a period of administration of the pharmaceutical composition.

135. The use according to any one of claims 59 to 134, wherein the level of androstenedione is reduced by at least about 25% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition.

136. The use according to any one of claims 59 to 134, wherein the level of androstenedione is reduced by at least about 30% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition.

137. The use according to any one of claims 59 to 134, wherein the level of androstenedione is reduced by at least about 50% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of androstenedione is relative to the level of androstenedione prior to administration of the pharmaceutical composition.

138. The use according to any one of claims 59 to 134, wherein the level of androstenedione is less than about 1.5 times a normal upper limit after a period of administration of the pharmaceutical composition.

139. The use according to any one of claims 59 to 134, wherein the level of androstenedione is within normal limits after a period of administration of the pharmaceutical composition.

140. The use according to any one of claims 59 to 139, wherein the level of testosterone is reduced by at least about 25% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition.

141. The use according to any one of claims 59 to 139, wherein the level of testosterone is reduced by at least about 30% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition.

142. The use according to any one of claims 59 to 139, wherein the level of testosterone is reduced by at least about 50% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of testosterone is relative to the level of testosterone prior to administration of the pharmaceutical composition.

143. The use according to any one of claims 59 to 139, wherein the level of testosterone is less than about 1.5 times a normal upper limit after a period of administration of the pharmaceutical composition.

144. The use according to any one of claims 59 to 139, wherein the level of testosterone is within normal limits after a period of administration of the pharmaceutical composition comprising the compound of Formula (I), or a pharmaceutically acceptable salt thereof.

145. The use according to any one of claims 59 to 125, wherein the level of 17-hydroxyprogesterone is reduced by at least about 50% and the level of androstenedione is reduced by at least about 50% after a period of administration of the pharmaceutical composition, wherein the reduction of the level of 17-hydroxyprogesterone and the level of androstenedione is relative to the level of 17-hydroxyprogesterone and the level of androstenedione prior to administration of the pharmaceutical composition.

146. The use according to any one of claims 59 to 125, wherein the level of 17-hydroxyprogesterone is less than about 1.5 times a normal upper limit and the level of androstenedione is less than about 1.5 times a normal upper limit after a period of administration of the pharmaceutical composition.

147. The use according to any one of claims 59 to 125, wherein the level of 17-hydroxyprogesterone is within normal limits and the level of androstenedione is within normal limits after a period of administration of the pharmaceutical composition.

148. The use according to any one of claims 105 to 147, wherein the subject exhibits a decrease in glucocorticoid burden after a period of administration of the pharmaceutical composition, wherein the decrease in glucocorticoid burden is relative to the glucocorticoid burden prior to administration of the pharmaceutical composition.

149. The use according to claim 148, wherein one or more symptoms of glucocorticoid burden selected from quality of life, fatigue, sleep, insulin resistance, glucose tolerance, glucose control, dyslipidemia, hyperlipidemia, bone mineral density, bone turnover, fat mass, weight, central obesity, blood pressure, hirsutism severity, menstrual cyclicity, control of testicular adrenal rest tumor and fertility, is improved after a period of administration of the pharmaceutical composition, wherein the improvement in the one or more symptoms is relative to the status of the one or more symptoms prior to administration of the pharmaceutical composition.

150. The use according to any one of claims 112 to 149, wherein the period of administration is at least about 4 weeks.

151. The use according to any one of claims 112 to 149, wherein the period of administration is at least about 24 weeks.

152. The use according to any one of claims 112 to 149, wherein the period of administration is at least about one year.

153. The use according to any one of claims 59 to 152, wherein the subject is a pediatric subject.

154. The use according to claim 153, wherein the pediatric subject is less than six years old or equal to six years old.

155. The use according to claim 153, wherein the pediatric subject is greater than six years old and less than eleven years old.

156. The use according to claim 153, wherein the pediatric subject is greater than ten years old and less than fifteen years old.

157. The use according to claim 153, wherein the pediatric subject is greater than fourteen years old and less than nineteen years old.

158. The use according to any one of claims 59 to 152, wherein the subject is an adult subject.

159. The use according to any one of claims 158, wherein the adult subject is greater than eighteen years old.

160. The use according to any one of claims 59 to 159, wherein the subject is female.

161. The use according to any one of claims 59 to 159, wherein the subject is male.

162. The use according to any one of claims 59 to 161, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is to be administered as a hydrochloric acid salt or p-toluenesulfonic acid salt.

163. The use according to any one of claims 59 to 161, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is to be administered as a p-toluenesulfonic acid crystalline salt.

164. The use according to any one of claims 59 to 163, wherein the subject presents with one or more testicular adrenal rest tumors.

165. The use according to any one of claims 59 to 164, wherein the congenital adrenal hyperplasia (CAH) is classic CAH.

166. Use of the pharmaceutical composition of any one of claims 1 to 56 in the manufacture of a medicament for treating testicular adrenal rest tumor in a subject.